DocGo Inc.

Listed Company

DCGOCIK 0001822359NasdaqAcceleratedSmaller ReportingServices-Health ServicesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$322.20M

Net Income

$-182.40M

Total Assets

$217.10M

Equity

$144.01M

Shares Out

98.75M

Op. Cash Flow

$34.45M

Business

DocGo Inc. delivers mobile and virtual healthcare and medical transportation through an integrated care delivery platform. It offers mobile health services (in-home and on-site clinical evaluation, diagnostics, triage and treatment), virtual care management and ambulance/medical transportation services. The company reports three segments: Mobile Health Services, Transportation Services (Ambulnz) and Corporate (shared services supporting operations). DocGo provides services to municipalities, hospitals, health systems, insurers, employers and government agencies across multiple U.S. states and the United Kingdom via clinician networks, vehicles and proprietary technology.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenues, net	322	617	624	441	319
Cost of revenues (exclusive of depreciation and amortization, which is shown separately below)	223	403	429	286	209
General and administrative	133	139	137	103	75
Depreciation and amortization	16	16	16	11	8
Legal and regulatory	24	17	13	9	4
Technology and development	14	12	11	5	3
Sales, advertising and marketing	1	2	3	5	5
Intangible asset impairment	31	0	0	—	—
Goodwill impairment	58	0	0	−3	0
Total expenses	500	588	609	419	303
(Loss) income from operations	−178	29	15	22	15
Interest (expense) income, net	−1	−2	2	762,685	—
(Loss) gain on change in fair value of contingent consideration	−2	9	1	0	0
Finite-lived intangible asset impairment	0	−8	0	—	—
Loss on equity method investments	−552,763	−316,044	−343,336	—	—
Equity investment impairment	−5	0	0	—	—
Loss on remeasurement of operating and finance leases	−42,367	−32,363	−866	1	0
(Loss) gain on disposal of assets	−39,668	23,682	−852,544	−21,173	−34,342
Other (expense) income	−532,418	228,666	−686,865	−987,482	−40,086
Total other expense (income)	−9	−939,724	1	950,264	−40,086
Net (loss) income before income tax expense	−187	28	16	23	20
Provision for income taxes	−9	−14	−6	8	−615,697
Net (loss) income	−196	13	10	31	19
Net (loss) income attributable to noncontrolling interests	−14	−7	3	−4	−5
Net (loss) income attributable to stockholders of DocGo Inc. and Subsidiaries	−182	20	7	35	24
Unrealized gain on investments, net of tax	85,635	0	0	—	—
Foreign currency translation adjustment	1	−263,036	743,699	773,707	16,038
Total comprehensive (loss) income	−181	20	8	35	24
Net (loss) income per share attributable to DocGo Inc. and Subsidiaries - Basic (in Dollars per share)	−1.84	0.2	0.07	0.34	0.3
Weighted-average shares outstanding - Basic (in Shares)	99	102	104	101	80
Net income per share attributable to DocGo Inc. and Subsidiaries - Diluted (in Dollars per share)	−1.84	0.18	0.06	0.34	0.25
Weighted-average shares outstanding - Diluted (in Shares)	99	109	106	103	95

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	51	89	59	157	176
Accounts receivable, net of allowance for credit loss of $8,299,053 and $5,873,942 as of December 31, 2025 and December 31, 2024, respectively	93	211	262	103	—
Prepaid expenses	5	4	—	—	2
Other current assets	4	338,665	—	—	—
Total current assets	152	304	339	271	256
Property and equipment, net	15	15	17	21	13
Intangibles, net	0	26	38	23	11
Goodwill	19	47	48	39	9
Restricted cash and cash equivalents	1	18	—	—	—
Restricted investments (amortized cost of $15,737,694 and $0 as of December 31, 2025 and December 31, 2024, respectively)	16	0	—	—	—
Operating lease right-of-use assets	12	12	10	9	4
Finance lease right-of-use assets	17	15	12	9	9
Investments	0	6	553,573	—	—
Deferred tax assets	538,864	8	12	10	—
Other assets	3	4	3	4	4
Total assets	217	456	490	393	310
Accounts payable	11	28	20	22	16
Accrued liabilities	43	50	91	32	35
Line of credit	0	30	25	0	25,881
Notes payable, current	51,740	12,515	28,131	664,913	600,449
Due to seller	336,982	28,656	8	26	—
Contingent consideration, current	3	5	—	—	—
Operating lease liability, current	5	4	3	2	1
Finance lease liability, current	6	5	4	3	3
Total current liabilities	67	122	170	100	58
Notes payable, non-current	183,843	5,215	41,586	1	—
Contingent consideration, non-current	5	0	—	—	—
Operating lease liability, non-current	8	9	7	7	3
Finance lease liability, non-current	11	10	8	6	7
Total liabilities	91	140	185	114	83
Commitments and contingencies	—	—	—	—	—
Common stock ($0.0001 par value; 500,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 98,640,059 and 101,910,883 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively)	9,864	10,191	10,406	10,241	10,013
Additional paid-in-capital	325	321	321	301	283
Accumulated deficit	−184	−1	−21	−29	−64
Accumulated other comprehensive income	2	1	1	741,206	−32,501
Total stockholders equity attributable to DocGo Inc. and Subsidiaries	144	321	301	273	220
Noncontrolling interests	−18	−6	4	6	7
Total stockholders equity	126	315	305	279	227
Total liabilities and stockholders equity	217	456	490	393	310

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation expense	5	6	5	4	—
Amortization of intangible assets	6	6	5	3	2
Amortization of finance lease right-of-use assets	5	5	6	3	3
Deferred income tax	8	3	−2	−10	0
Accretion of discount related to restricted investments	−309,842	0	0	—	—
Loss on equity method investments	552,763	316,044	343,336	—	—
Bad debt expense	12	5	4	4	4
Stock-based compensation	17	14	21	8	1
Loss on liquidation of business	0	0	70,284	0	0
Intangible asset impairment	31	8	0	—	—
Accounts receivable	112	41	−161	−8	−58
Prepaid expenses and other current assets	−3	13	−11	−4	−961,165
Other assets	409,156	−1	1	2	−2
Accounts payable	−18	8	−2	4	12
Accrued liabilities	−10	−42	59	−6	21
Operating lease liabilities and right-of-use assets	200,221	32,834	0	—	—
Net cash provided by (used in) operating activities	34	70	−64	29	−2
Purchase of property and equipment	−5	−4	−7	−3	−5
Purchase of intangibles	−3	−2	−3	−2	−2
Acquisition of businesses, net of cash acquired	−16	0	−20	−33	−1
Purchase of restricted investments	−29	0	0	—	—
Purchase of equity method investments	−4,784	−310,450	−298,932	0	−655,876
Purchase of equity securities	0	−5	0	0	—
Proceeds from sale and maturity of restricted investments	13	0	0	—	—
Proceeds from disposal of property and equipment	202,167	274,427	747,088	3,000	74,740
Net cash used in investing activities	−39	−11	−30	−38	−9
Proceeds from revolving credit line	0	45	25	0	8
Repayments of revolving credit line	−30	−40	0	−25,881	—
Proceeds from notes payable	258,700	0	0	—	—
Repayments of notes payable	−41,247	−51,987	−25,926	−925,151	−604,826
Due to seller	−877,713	−3	−14	−3	−595,528
Acquisition of noncontrolling interest	0	−2	0	0	—
Earnout payments on contingent liabilities	−2	−4	−5	0	0
Distributions paid to noncontrolling interest	−175,831	−1	0	0	—
Proceeds from exercise of stock options	0	26,330	2	2	628,592
Payments for taxes related to shares withheld for employee taxes	−2	−1	−2	0	0
Common stock repurchased	−11	−14	0	−4	0
Payments on obligations under finance lease	−5	−4	−4	−3	−2
Net cash (used in) provided by financing activities	−51	−24	1	−6	155
Effect of exchange rate changes on cash and cash equivalents	595,803	−190,639	1	761,232	−21,414
Net (decrease) increase in cash, cash equivalents, restricted cash and restricted cash equivalents	−55	35	−92	−15	145
Cash paid for interest	2	2	250,100	197,005	315,272
Cash paid for interest on finance lease liabilities	958,553	769,041	600,239	559,596	525,476
Cash paid for income taxes, net of refunds	6	6	10	2	615,697
Right-of-use assets obtained in exchange for lease liabilities	12	14	8	5	5
Remeasurement of finance lease right-of-use asset due to lease modification	0	300,000	0	0	—
Property and equipment in accounts payable	52,866	221,639	271,292	—	—
CRMS True-up Payment through issuance of stock	0	2	0	0	—
Receivables exchanged for trade credits	0	0	2	0	0
Pre-acquisition receivables written off through due to seller	0	5	0	0	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro